Key facts
- Mammotome received CE mark approval for HydroMARK Plus markers in Europe.
- The markers use proprietary hydrogel technology.
- Features enhance marker stability and visibility in breast care.
Mammotome, a subsidiary of Danaher, has announced the expansion of access to its innovative HydroMARK Plus breast biopsy site markers across Europe following the attainment of CE mark approval. This regulatory milestone signifies that the HydroMARK Plus markers, which incorporate proprietary hydrogel technology, will now be more widely available to healthcare providers throughout the European market. The markers are engineered with specific features intended to enhance their stability and visibility within the breast tissue, aiming to improve the precision and effectiveness of breast care procedures. The CE mark approval expands access to the HydroMARK Plus markers throughout Europe, combining exclusive hydrogel technology with features designed to promote marker stability and visibility in breast care.